🇺🇸 FDA
Patent

US 10981986

Fusions of antibodies to CD38 and attenuated interferon alpha

granted A61KA61K38/00A61K47/642

Quick answer

US patent 10981986 (Fusions of antibodies to CD38 and attenuated interferon alpha) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Grant date
Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/00, A61K47/642, A61P, A61P35/00